Prostate Specific Antigen News and Research

RSS

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.

25 Aug 2015

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.

17 Aug 2015

Testosterone administration not associated with atherosclerosis progression among older men

Among older men with low testosterone levels, testosterone administration for 3 years compared with placebo did not result in a significant difference in the rates of change in atherosclerosis (thickening and hardening of artery walls), nor was it associated with improved overall sexual function or health-related quality of life, according to a study in the August 11 issue of JAMA.

12 Aug 2015

Prostate cancer discovery may improve treatment strategies

Scientists from Cancer Research UK have discovered that there are five different types of prostate cancer and have found a way of distinguishing between them. These findings could change how the condition is treated, providing more effective therapies where they are needed the most.

30 Jul 2015

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Current U.S. Preventive Services Task Force Guidelines for prostate screening may be impacting the detection of high-risk prostate cancer.

14 Jul 2015

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies.

23 Jun 2015

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men.

19 Jun 2015

Simple test could help identify genetically inherited risk for prostate cancer

Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.

18 Jun 2015

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, they experienced a reduction in their testosterone levels leading to hypogonadism (little to no production of sex hormones).

14 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

Pathology expert shares vital information about prostate cancer

Requesting a copy of your pathology report, asking questions of your doctor and playing an active role in decision-making are important ways that men should take control of their health.

10 Jun 2015

QUT cancer and eye researchers named in Queen's Birthday honours

Professor Clements is honoured for her outstanding contribution to biomedical research, particularly prostate cancer research, and for her success in generating ongoing funding to support the establishment of critically-needed national medical research facilities.

10 Jun 2015

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

9 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel and cabazitaxel. For example, docetaxel is commonly used as the "first-line" therapy, while cabazitaxel is used as the "second-line" therapy.

30 May 2015

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer.

29 May 2015

Active surveillance appears to be safer management strategy for prostate cancer patients

Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer will be presented during the 110th Annual Scientific Meeting of the American Urological Association.

17 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

Study shows that periodontal treatment can reduce symptoms of prostatitis

Treating gum disease reduced symptoms of prostate inflammation, called prostatitis, report researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center.

6 May 2015

Prostate Specific Antigen News and Research

New research finds five different types of prostate cancer

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Testosterone administration not associated with atherosclerosis progression among older men

Prostate cancer discovery may improve treatment strategies

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Targeted molecular-imaging method could help identify early stages of prostate cancer

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Simple test could help identify genetically inherited risk for prostate cancer

Men who use finasteride to treat benign prostate enlargement experience worsening ED

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

Pathology expert shares vital information about prostate cancer

QUT cancer and eye researchers named in Queen's Birthday honours

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

Green tea components may help prevent prostate cancer development in at-risk men

Active surveillance appears to be safer management strategy for prostate cancer patients

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Study shows that periodontal treatment can reduce symptoms of prostatitis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News